AntriaBio

AntriaBio

AntriaBio (OTC: ANTB) is a drug development company that has a long-acting insulin product for diabetes and is looking in emerging markets to accelerate its development. AntriaBio’s lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is to be administered by subcutaneous injection and is intended for use in patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.

< Back to Portfolios